Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cortexyme Inc (NQ: CRTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cortexyme Inc < Previous 1 2 Next > Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 July 27, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 July 27, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections June 21, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Appoints June Bray to its Board of Directors June 13, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Appoints Dr. Philip Low to Its Board of Directors May 20, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Successfully Completes Acquisition of Novosteo May 20, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases May 12, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Announces Agreement to Acquire Novosteo May 10, 2022 From Cortexyme, Inc. Via Business Wire NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc. April 29, 2022 San Diego, CA -- (SBWIRE) -- 04/29/2022 -- Certain directors of Cortexyme, Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX April 05, 2022 From The Rosen Law Firm, P.A. Via Business Wire Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population March 21, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors March 15, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme to Present New GAIN Trial Data at AD/PD 2022 March 14, 2022 From Cortexyme, Inc. Via Business Wire CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm February 24, 2022 From Bragar Eagel & Squire, P.C. Via Business Wire NASDAQ:CRTX Shareholder Notice: Investigation over Potential Securities Laws Violations by Cortexyme, Inc. February 24, 2022 San Diego, CA -- (SBWIRE) -- 02/24/2022 -- Cortexyme, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm February 23, 2022 From Bragar Eagel & Squire Via Business Wire Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm February 18, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Investigation Alert: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm February 17, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm February 16, 2022 Los Angeles - (NewMediaWire) - February 16, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme,... Via NewMediaWire INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm February 15, 2022 From The Schall Law Firm Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm February 14, 2022 From The Schall Law Firm Via Business Wire EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX February 14, 2022 From Rosen Law Firm Via Business Wire Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones February 01, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Announces Change in Executive Leadership Team February 01, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application January 26, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th November 23, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021 November 11, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th November 04, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression October 26, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021 September 27, 2021 From Cortexyme, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
